Keyword: Ibrance

A new look at cancer survivors' media habits shows that where they get data and to what degree they value it depends on when they were diagnosed.

Integration following a large-scale M&A is too much a distraction from Pfizer's "best pipeline in our history," said Bourla.

A pile of evidence for CDK 4/6 cancer drugs hasn’t yet persuaded some physicians to try the meds, but Pfizer's going all out to change their minds.

Pfizer’s Ibrance failed to prove it could help some patients live longer, but executives say those study results still make a “compelling” case.

Lilly did not make a plausible case that its drug is more cost-effective than other CDK 4/6 inhibitors, England's drug-price watchdog said.

As a big ESMO 2018 kicks off, here are the studies we're most excited to see.

Pfizer breast-cancer fighter Ibrance posted a rare sales miss Tuesday, but it wasn't because Novartis and Lilly are stealing its share.

Pfizer’s Ibrance is OK'd to treat certain breast cancer patients who've relapsed, but new data suggests it may not help them live longer.

Just how big has the wave of new cancer drug ads been? Syneos analyzed DTC data from the past decade to find out.